Nasdaq · Healthcare
TriSalus Life Sciences, Inc. (TLSI)
As-reported financials and recent SEC filings for TriSalus Life Sciences, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$45.2M
Net income
$-39.2M
Net margin
-86.9%
Diluted EPS
$-1.84
ROE
115.8%
P/E (TTM)
—
Market cap
—
Debt / equity
-1.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $45.2M | $29.4M | $18.5M | $12.4M | — |
| Gross profit | $38.2M | $25.3M | $15.9M | $10.1M | — |
| Operating income | $-26.9M | $-36.2M | $-54.5M | $-36.4M | $-3.0M |
| Net income | $-39.2M | $-30.0M | $-59.4M | $-47.2M | $4.8M |
| Diluted EPS | $-1.84 | $-1.31 | $-2.26 | $-1.80 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-06
View on EDGAR →42026-07-01
View on EDGAR →52026-07-01
View on EDGAR →42026-07-01
View on EDGAR →52026-07-01
View on EDGAR →42026-06-29
View on EDGAR →32026-06-29
View on EDGAR →SCHEDULE 13G/A2026-05-20
View on EDGAR →Largest Healthcare peers
Go deeper on TLSI
Search TriSalus Life Sciences, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.